Incidence of pseudoprogression

PublicationNo. of PatientsResponse CriteriaaCriteria for Early ProgressionbNo. of Early ProgressionPseudo-Progression (% of Early Progression)Pseudo-Progression (% of Patients)
Brandes et al11103Enhancement increase for earlier progression than Macdonald criteria4 Weeks50/10332/5032/103
J Clin Oncol 200820(48.5%)(64%)(31%)
Taal et al85Macdonald Criteria4 Weeks36/8515/31a15/85
Cancer 200810(42%)(48%)(17.6%)
Clarke et al80Increased contrast enhancementNot specified33/808/25a8/80
(abstract) J Clin Oncol 200817(41%)(32%)(10%)
Gerstner et al45Macdonald Criteria17–28 Days24/4513/2413/45
J Neurooncol 200918(53%)(54%)(29%)
Jefferies et al15Not specified6 Months9/153/93/15
abstract Clin Oncol 200719(60%)(33%)(20%)
Chaski et al54Increased contrast enhancement6 Months25/543/253/54
Surg Neurol 200914(46%)(12%)(5.5%)
Sanghera et al104RECIST8 Weeks27/1047/22a7/104
Can J Neurol Sci 201016(26%)(32%)(7%)
Mangla et al36Macdonald Criteria4 Weeks19/367/197/36
Radiology 201015(53%)(37%)(20%)
  • a —All were defined in the text.

  • b Defined as increase of the enhancing portion of the lesion in the follow-up MR exam.